Memorial Sloan Kettering and Yale Cancer Center Deploy Triomics AI Platform to Accelerate Clinical Trial Matching
核心洞察
Memorial Sloan Kettering Cancer Center is collaborating with Triomics (搜索) to deploy an AI-powered clinical trial matching platform that reduces patient screening time from 45 minutes to near real-time processing.
Yale Cancer Center and Smilow Cancer Hospital (搜索) will expand Triomics (搜索)' AI screening system across their entire portfolio of over 400 active oncology (搜索) clinical trials.
The platform automatically analyzes patient records and provides ranked trial matches with detailed rationale and source citations, enabling research teams to identify more eligible patients efficiently.
Memorial Sloan Kettering Cancer Center (MSK) and Yale Cancer Center are implementing Triomics (搜索)' artificial intelligence platform to revolutionize clinical trial patient matching and screening processes. The collaboration aims to address the time-intensive challenge of manually screening patient records against extensive clinical trial portfolios, which can take up to 45 minutes per patient when records include clinician notes and PDFs.
AI-Powered Screening Transforms Manual Processes
Triomics (搜索)' generative AI platform automatically analyzes patient records, identifies eligible trials, and provides itemized rationale with source citations. The system reads through longitudinal medical records and eligibility criteria for all active clinical trials, generating ranked shortlists of trials for each patient with upcoming appointments, complete with clear per-criterion explanations and links to original sources.
"Real-time, evidence-linked matching transforms clinical trial screening from a bottleneck to an efficient, streamlined process," said Joe Lengfellner, Senior Director, Clinical Research Informatics & Technology at MSK. "This collaboration will enable our teams to surface opportunities that might otherwise be missed, allowing us to offer trials to more patients."
Expansion Across Major Cancer Centers
At Yale Cancer Center and Smilow Cancer Hospital (搜索), the platform will be deployed across the entire portfolio of over 400 active oncology (搜索) clinical trials. As Connecticut's only National Cancer Institute-designated Comprehensive Cancer (搜索) Center, Yale Cancer Center selected Triomics (搜索) after thorough evaluation of the technology's capabilities.
"We're always looking for ways to make clinical research more efficient and accessible to our patients," said Ian Krop, MD, PhD, Professor of Medicine (Medical Oncology (搜索)), and Medical Director, Yale Cancer Center Clinical Trials Office. "After a thorough evaluation, we are excited for the Triomics (搜索)' platform to bring ease of access, structure, and transparency to the process, allowing our teams to focus more on enabling patients to enroll to appropriate trials and less on searching through charts."
Clinical Validation and Implementation Strategy
The technology has demonstrated expert-level accuracy in clinical trial screening as published in Nature Digital Medicine. At MSK, the deployment follows a two-phase rollout plan developed by the MSK Clinical Research Innovation Consortium (搜索) (CRIC) and MSK iHub teams, with plans to encompass MSK's full clinical trial portfolio.
Triomics (搜索) participated in MSK's selective iHub Challenge program in 2024 before joining the MSK Innovation Hub (搜索). "Working with MSK through the iHub Challenge gave us direct access to senior research and innovation leaders, allowing the team to validate our technology quickly and accelerate implementation," noted Sebastien Rhodes, VP of Strategy & Operations at Triomics.
Enhanced Feasibility Assessment
Beyond patient screening, the platform supports trial feasibility assessment by rapidly evaluating eligibility criteria using real-world patient data. "By integrating the Triomics (搜索) platform into our feasibility process, we can rapidly assess trial eligibility criteria using real-world patient data," said Alyssa Gateman, MPH, CCRP Executive Director of the Yale Cancer Center Clinical Trials Office. "This data-driven approach enhances our ability to anticipate enrollment challenges and ensure that new studies are positioned for success from the start."
The collaboration includes strategic advisory roles, with Paul Sabbatini, Senior Vice President for Clinical Research at MSK, joining Triomics (搜索)' Customer Advisory Board to guide the responsible scale-up of the platform across the company's network of partner cancer (搜索) centers.
"Collaborating with MSK represents a significant milestone. MSK's leadership in clinical research and innovation makes it an ideal partner as we work together to demonstrate how generative AI can transform oncology (搜索) trial operations and accelerate access to cutting-edge therapies," said Sarim Khan, Triomics (搜索)' Co-Founder and CEO.